These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 9834016)
1. Anticoagulant activity in non-immunoglobulin fraction from plasma of patients with antiphospholipid syndrome. Sugimura M; Su F; Kanayama N; Kobayashi H; Kobayashi T; Terao T Semin Thromb Hemost; 1998; 24(5):473-7. PubMed ID: 9834016 [TBL] [Abstract][Full Text] [Related]
2. Anti-beta2-glycoprotein I autoantibodies, in vitro thrombin generation, and the antiphospholipid syndrome. Hanly JG; Smith SA J Rheumatol; 2000 Sep; 27(9):2152-9. PubMed ID: 10990227 [TBL] [Abstract][Full Text] [Related]
3. Activated protein C resistance and lupus anticoagulant activity induced by plasma and purified monospecific human IgG anti-beta2-glycoprotein-I antibodies. Viveros ME; Cabiedes J; Reyes E; Cabral AR Rev Invest Clin; 2005; 57(4):563-71. PubMed ID: 16315641 [TBL] [Abstract][Full Text] [Related]
4. IgG reactivity to phospholipid-bound beta(2)-glycoprotein I is the main determinant of the fraction of lupus anticoagulant activity quenched by addition of hexagonal (II) phase phospholipid in patients with the clinical suspicion of antiphospholipid-antibody syndrome. Safa O; Crippa L; Della Valle P; Sabbadini MG; Viganò D'Angelo S; D'Angelo A Haematologica; 1999 Sep; 84(9):829-38. PubMed ID: 10477458 [TBL] [Abstract][Full Text] [Related]
5. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Atsumi T; Ieko M; Bertolaccini ML; Ichikawa K; Tsutsumi A; Matsuura E; Koike T Arthritis Rheum; 2000 Sep; 43(9):1982-93. PubMed ID: 11014348 [TBL] [Abstract][Full Text] [Related]
6. Interference of lupus anticoagulants in prothrombin time assays: implications for selection of adequate methods to optimize the management of thrombosis in the antiphospholipid-antibody syndrome. Della Valle P; Crippa L; Garlando AM; Pattarini E; Safa O; Viganò D'Angelo S; D'Angelo A Haematologica; 1999 Dec; 84(12):1065-74. PubMed ID: 10586206 [TBL] [Abstract][Full Text] [Related]
7. Identification of thrombin antibodies in patients with antiphospholipid syndrome. Miesbach W; Matthias T; Scharrer I Ann N Y Acad Sci; 2005 Jun; 1050():250-6. PubMed ID: 16014540 [TBL] [Abstract][Full Text] [Related]
8. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus. Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209 [TBL] [Abstract][Full Text] [Related]
9. Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants. Liestøl S; Sandset PM; Jacobsen EM; Mowinckel MC; Wisløff F Br J Haematol; 2007 Jan; 136(1):131-7. PubMed ID: 17092306 [TBL] [Abstract][Full Text] [Related]
11. Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human beta2-glycoprotein I. Arnout J; Meijer P; Vermylen J Thromb Haemost; 1999 Jun; 81(6):929-34. PubMed ID: 10404770 [TBL] [Abstract][Full Text] [Related]
12. Anti-beta2-glycoprotein I (beta2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the beta2GPI binding to phospholipids. Takeya H; Mori T; Gabazza EC; Kuroda K; Deguchi H; Matsuura E; Ichikawa K; Koike T; Suzuki K J Clin Invest; 1997 May; 99(9):2260-8. PubMed ID: 9151800 [TBL] [Abstract][Full Text] [Related]
13. [Antiphospholipid syndrome and stroke]. Kitagawa Y Rinsho Shinkeigaku; 2005 Nov; 45(11):852-5. PubMed ID: 16447744 [TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of lupus anticoagulant (LA) antibodies: LA activity in dilute Russell's Viper Venom Time and dilute Kaolin Clotting Time detect different populations of antibodies in patients with the "antiphospholipid" syndrome. Kandiah DA; Krilis SA Thromb Haemost; 1998 Aug; 80(2):250-7. PubMed ID: 9716148 [TBL] [Abstract][Full Text] [Related]
15. [Phosphatidylserine-dependent anti-prothrombin antibody as a new marker for the diagnosis of antiphospholipid syndrome]. Ieko M; Nakabayashi T; Tarumi T; Yoshida M; Naito S; Atsumi T; Koike T Rinsho Byori; 2006 Mar; 54(3):256-62. PubMed ID: 16637574 [TBL] [Abstract][Full Text] [Related]
16. Autoantibodies to beta2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests. Day HM; Thiagarajan P; Ahn C; Reveille JD; Tinker KF; Arnett FC J Rheumatol; 1998 Apr; 25(4):667-74. PubMed ID: 9558167 [TBL] [Abstract][Full Text] [Related]
17. Thrombin generation measured ex vivo following microvascular injury is increased in SLE patients with antiphospholipid-protein antibodies. Musiał J; Swadźba J; Jankowski M; Grzywacz M; Bazan-Socha S; Szczeklik A Thromb Haemost; 1997 Oct; 78(4):1173-7. PubMed ID: 9364980 [TBL] [Abstract][Full Text] [Related]
19. Thrombin generation assay as a possible tool for assessment of reduced activity of clotting factors induced by antiphospholipid antibodies and in-vitro evaluation of treatment options. Livnat T; Zivelin A; Tamarin I; Guetta V; Salomon O Blood Coagul Fibrinolysis; 2009 Dec; 20(8):661-6. PubMed ID: 19730246 [TBL] [Abstract][Full Text] [Related]
20. Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C. de Laat B; Eckmann CM; van Schagen M; Meijer AB; Mertens K; van Mourik JA Blood Coagul Fibrinolysis; 2008 Dec; 19(8):757-64. PubMed ID: 19002041 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]